Project Description

Faraday
Faraday Pharma is Developing a Treatment to Increase Metabolic Flexibility And Extend Lives

Date & Time:

March 9, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval

About the Event:

As we age, our body deteriorates and the ability to fight off disease and recover from traumatic events like a heart attack and surgery becomes harder and harder – one of the key causes is a reduction in metabolic flexibility.

Faraday Pharmaceuticals has developed a treatment that restores metabolic flexibility – a key to helping patients recover from acute events faster and more completely. This may have broader effects on longevity as well.

It all began when Dr. Mark Roth, a 2007 MacArthur Fellow, started to wonder how people who fall through the ice on frozen lakes can be reanimated with little or no long-term health effects. He found that though the heart and lungs weren’t functioning, the muscles were healthy and still maintained energy. Metabolic flexibility allowed them to slow their metabolism to the point where they could survive.

Faraday Pharma is entering a Phase 3 study of their drug FDY-5301, which uses the same principle, to help patients who suffer from Myocardial Infarction reduce the effects of reperfusion following a heart attack. Data shows that FDY-5301 reduces infarction size which correlates directly with elevated survival and recovery rates.

Join our webinar to learn more about how Faraday is improving metabolic flexibility to help people live longer, better.

Share this Event

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.